Aberdeen Group plc Buys 160,716 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Aberdeen Group plc increased its stake in Janux Therapeutics by 250.8%, owning 224,788 shares worth approximately $6.1 million, reflecting growing institutional interest in the company.
• Analysts have set a positive outlook on Janux Therapeutics, with an average rating of "Buy" and a target price of $86.90, indicating strong potential for price appreciation.
• Janux Therapeutics reported a quarterly loss of ($0.55) earnings per share, which missed analyst expectations, highlighting ongoing financial challenges as the company continues its clinical trials for cancer therapies.

Aberdeen Group plc increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 250.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,788 shares of the company's stock after acquiring an additional 160,716 shares during the quarter. Aberdeen Group plc owned 0.38% of Janux Therapeutics worth $6,069,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in JANX. GAMMA Investing LLC raised its holdings in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares during the period. US Bancorp DE raised its holdings in shares of Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after acquiring an additional 1,658 shares during the period. Russell Investments Group Ltd. increased its stake in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics in the 4th quarter valued at approximately $59,000. Finally, FNY Investment Advisers LLC increased its stake in Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded up $0.63 during trading hours on Tuesday, hitting $23.64. 459,018 shares of the stock were exchanged, compared to its average volume of 866,966. The company's 50 day moving average is $24.52 and its 200 day moving average is $27.44. The firm has a market capitalization of $1.42 billion, a P/E ratio of -13.13 and a beta of 2.86. Janux Therapeutics, Inc. has a one year low of $21.97 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JANX shares. Piper Sandler started coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 price objective on the stock. Raymond James Financial started coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.